摘要
Abstract
Objective:To observe the effect and safety of Dupilumab in the treatment of moderate to severe atopic dermatitis(AD)in children aged 3-12 years.Method:The clinical data of 35 children with moderate to severe AD aged 3-12 years who diagnosed and treated in Zhongshan Hospital Xiamen University from July 2022 to December 2023 were retrospectively analyzed,all children were treated with basic therapy and Dupilumab,the eczema area and severity index(EASI),scoring atopic dermatitis(SCORAD)score and investigator global assessment(IGA)score were evaluated and compared before treatment and 4 weeks,8 weeks,12 weeks and 16 weeks of treatment.Result:At 4 weeks of treatment,the severity of disease was significantly improved,with the prolongation of treatment time,the EASI score,SCORAD score and IGA score continued to decrease,and the differences were statistically significant(P＜0.001);the most obvious improvement of skin lesions in various parts of body was trunk[90.0%(73.2%,94.5%)],followed by upper limbs[85.0%(69.2%,92.3%)],head and neck[74.0%(58.3%,85.3%)],lower limbs[76.0%(61.0%,87.0%)],and the overall[80.0%(72.3%,88.3%)],the differences were statistically significant(P＜0.001).Among 35 children,8 cases(22.9%)had adverse reactions during treatment,and none of adverse reactions led to drug withdrawal.Conclusion:The treatment of moderate to severe AD in children aged 3-12 years old with Dupilumab has good effect and safety,the improvement of trunk skin lesions in each part was the most obvious..关键词
中重度/特应性皮炎/度普利尤单抗/湿疹面积及严重程度指数/3～12岁Key words
Moderate to severe/Atopic dermatitis/Dupilumab/Eczema area and severity index/Aged 3-12 years
